BioSpace News Archive

Sign in front of Pfizer in Quebec, Canada

Pfizer Phase III Prostate Cancer Win Builds Case for Broader Label for Talzenna-Xtandi Combo

The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, potentially covering all patients with metastatic castration-resistant prostate cancer regardless of biomarker status.

October 10, 2024

·

2 min read

·

Tristan Manalac

Gene therapy

7 Children Receiving Bluebird’s Gene Therapy Developed Blood Cancers: Study

The pediatric patients, with a rare neurodegenerative disease, were treated with bluebird bio’s Skysona to slow the progression of neurologic dysfunction. Six patients developed myelodysplastic syndrome and one patient developed acute myeloid leukemia.

October 10, 2024

·

2 min read

·

Tristan Manalac

Pictured: Astellas' Americas headquarters in Illin

Layoffs

Astellas Cuts 24 Universal Cells Roles in Seattle, Transfers 12 to Japan

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

October 10, 2024

·

1 min read

·

Angela Gabriel

A man is holding an umbrella while standing on a cliff. The umbrella is green and the man is looking up at the sky. Concept of danger and uncertainty, as the man is on the edge of a cliff

Bankruptcy

Gritstone Files for Bankruptcy in Effort to Save Clinical Research

Vaccine biotech Gritstone bio is filing for bankruptcy while securing a stalking horse bid from an unnamed party, which the company hopes will save its clinical research in cancer and infectious disease.

October 10, 2024

·

1 min read

·

Annalee Armstrong

Drug Development

How AI Could Ease Tension in Clinical Trials

In the third episode of our mini series on artificial intelligence, Lori and guests continue their exploratory discussion on AI and the opportunity in patient lives.

October 10, 2024

·

1 min read

·

Lori Ellis

GSK's headquarters office building in Poznan, Poland

Legal

GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the product liability cases regarding allegations that GSK’s heartburn drug could cause cancer. Analysts say separate concerns remain about its vaccines business.

October 10, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Adding Vagus Nerve Stimulation to Training Sessions May Boost How Well Sounds Are Perceived

October 10, 2024

·

5 min read

Press Releases

Roche Canada Announces Columvi® (glofitamab for injection) is Publicly Reimbursed in 7 Provinces, Including Quebec, Ontario, Manitoba, Saskatchewan, Nova Scotia, and Newfoundland